Skip to main content
Premium Trial:

Request an Annual Quote

Brain Researchers Collaborate to Form Neuromics Company

NEW YORK, Oct 10 – Recently retired editor-in-chief of Science Floyd Bloom said Tuesday he had formed a new company, Neurome Technologies, to bring automated and high-throughput gene expression analysis into the field of neuroscience.

“Our initial business model is to collaborate with pharmaceutical companies in applying the methods of gene expression and protein expression mapping and put them into the context of the chemical anatomy of the brain—the neurotransmitters receptors and circuits that are linked to neurological and behavioral disorders,” said Bloom, CEO of the new La Jolla, Calif.-based venture.

Some scientists estimate that as many as half of all genes are expressed only in the brain.

Bloom, who will retain his position as head of neuropharmacology at the Scripps Research Institute, said that Neurome would announce a partnership with a major pharmaceutical company within the next 10 days. Neurome has so far raised $9 million in financing.

Warren Young, a computer-based neuroscientist at Scripps, will serve as the company’s CTO, and John Morrison of Mount Sinai School of Medicine will be CSO. Both Scripps and Mount Sinai, founding shareholders of Neurome, are both involved in developing Neurome’s proprietary technologies.

These technologies include MiceSlice, for standardized preparation of brain section tissues, NeuroZoom, for computer-aided extraction, analysis, and visualization of quantitative data from microscope images of the brain, BrainArchive, an electronic brain atlas for archiving, integrating, and comparing   brain structure and circuitry data, and BrainPrint for automated comparison of quantitative, spatial, and volumetric data from manipulated, wild-type, and control mice.

Young said that recent advances in genomics and computer science were driving the demand for procedures that could rapidly extract accurate, reliable quantitative data on brain structure.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.